Zynerba Press Releases

11 Jun 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

30 May 19 Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds

29 May 19 Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

28 May 19 Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

8 May 19 Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

6 May 19 Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

2 Apr 19 Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

11 Mar 19 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights

7 Mar 19 Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

26 Feb 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol